Fennec Pharmaceuticals Inc (FENC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $410.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fennec Pharmaceuticals Inc (FENC) P/E Ratio & Valuation Multiples
Fennec Pharmaceuticals (FENC) trades at 159.5x trailing earnings and 6.8x sales. Its P/S of 6.8x is above its 5-year median of 5.9x. Its forward P/E is 13.6x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 1072.8% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 159.5x |
| Forward P/E | 13.6x |
| Price to sales | 6.8x |
| Price to book | 9.1x |
| EV/EBITDA | 102.2x |
| PEG | 1.5 |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 6.8x | 5.9x | N/A |
Valuation History
Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 3.6x in 2024 to 164.9x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $7.70 | 5.0x | 6.8x |
| 2024 | $6.32 | 3.6x | N/A |
| 2023 | $11.22 | 14.1x | N/A |
| 2022 | $9.60 | 164.9x | N/A |
| 2021 | $4.40 | N/A | 7.3x |
| 2020 | $7.45 | N/A | 6.1x |
| 2019 | $6.49 | N/A | 11.0x |
| 2018 | $6.38 | N/A | 6.0x |
| 2017 | $10.02 | N/A | 5.7x |
| 2016 | $2.14 | N/A | 7.6x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FENC
What is FENC's forward P/E ratio?
Fennec Pharmaceuticals has a forward P/E ratio of 13.6x.
Is FENC stock overvalued?
GNG's valuation label for FENC is Undervalued.
What is FENC's price to sales ratio?
Fennec Pharmaceuticals has a price to sales ratio of 6.8x.
What is FENC's PEG ratio?
Fennec Pharmaceuticals has a PEG ratio of 1.5.
FENC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors